SEPN SEPTERNA INC

Septerna to Participate in Upcoming Investor Conferences

Septerna to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September:

Cantor Global Healthcare Conference 2025

Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET

2025 Wells Fargo Healthcare Conference

Fireside chat on Friday, September 5, 2025, at 8:45 a.m. ET

Live webcasts of the presentations will be available in the investors section of the company’s website at Replays will be archived for at least 30 days following each event.

About Septerna

Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit .

Investor Contact:

Renee Leck, THRUST

Media Contact:

Carly Scaduto



EN
27/08/2025

Underlying

SEPNSEPTERNA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEPTERNA INC

 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna to Participate in Upcoming Investor Conferences

Septerna to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025 Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET 2025 Wells Fargo Healthcare ConferenceFireside chat on Friday, September 5, 2025, at 8:45 a.m. ET Live webca...

18h / 26m 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Announces Dosing of the First Participants in Phase 1 Clinica...

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phas...

August 21, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Highlights Business Progress and Reports Second Quarter 2025 ...

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming miles...

August 11, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna to Present at Jefferies Global Healthcare Conference

Septerna to Present at Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:45 p.m. ET in New York. A live webcast of the presentation will be available and in the investors section of the company’s website at . The webcast will be archiv...

May 29, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Highlights Business Progress and Reports First Quarter 2025 F...

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, in Third Quarter of 2025 Ended First Quarter 2025 with $398.2 Million in Cash, Cash Equivalents and Marketable Securities; Novo Nordisk Colla...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch